about
A laboratory in your pocketDetermination of the natural history of aspirin resistance among stable patients with cardiovascular diseaseEffects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trialSafety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulationClopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromesAntiplatelet effect of aspirin in patients with cerebrovascular diseaseClopidogrel: how good is it and how does it work?Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction studyThe use of anti-inflammatory analgesics in the patient with cardiovascular disease: what a painAnalysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trialsResistance to antiplatelet resistance is it justified?Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro studyThe role of the platelet in the pathogenesis of atherothrombosisGlycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarctionEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialClopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsAntiplatelet therapy: aspirinLack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trialAspirin dose for the prevention of cardiovascular disease: a systematic reviewRelationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary interventionPatients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialOptimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studiesProlonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trialLack of evidence of a clopidogrel-statin interaction in the CHARISMA trialAn analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trialOral antiplatelet therapy for percutaneous coronary revascularizationThe emerging field of mobile healthPrivacy and security in the era of digital health: what should translational researchers know and do about it?Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.Development of a multi-institutional cohort to facilitate cardiovascular disease biomarker validation using existing biorepository samples linked to electronic health records.Prevalence of heart failure signs and symptoms in a large primary care population identified through the use of text and data mining of the electronic health record.Early detection of heart failure with varying prediction windows by structured and unstructured data in electronic health records.Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.Early Detection of Heart Failure Using Electronic Health Records: Practical Implications for Time Before Diagnosis, Data Diversity, Data Quantity, and Data Density.Heparin-induced thrombocytopenia and cardiovascular diseases.Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.
P50
Q27276923-1D5B5FA3-13C3-42C6-BAE6-1049D3FCEF79Q28165549-4F5DE141-5C0F-4355-8E27-B1C3E1B9F968Q28165710-3AFCA9C7-2C3F-4307-9075-3B6C2125AE66Q28167576-44DD7C65-CD98-4963-80D2-5539A67C8A3EQ28167896-A0A0E865-3FB7-4D6B-8D38-0AACB130F819Q28168149-3A75496C-B585-4E8B-827A-AC6EBE9DB830Q28168869-534773C7-0561-4FEA-975E-74BAF4B82BD5Q28171113-BC122B90-68A7-45F7-8EC5-8A6D1433EB5DQ28174157-44DB2A4F-A149-452C-9702-F77C0F3E4C85Q28174968-3D98A21D-6413-471D-991A-8162792B7F31Q28176622-94C1E33A-D3E7-4F4B-9B2E-F5BF46094C7AQ28192429-DD7CF35A-D5F8-45F7-A5FF-1D643E39C532Q28193015-B79FE614-60C6-4B0F-A70E-685F01796F09Q28193157-24B54B6D-3F61-4284-B8E8-28DECCF2F1F5Q28194232-DA783700-6D6E-4552-9F62-653FD9376387Q28195656-93D99B2E-5F0D-4A13-9F54-7BCF5FD60882Q28195825-837998B0-05E4-4334-9C62-A218ECCEB999Q28199508-BDCA736D-7BAC-4434-BB7F-55FAE12EEDE1Q28210030-C2475B2B-A66D-42DB-B793-5348083AF249Q28210485-BD9871F5-B6B6-4796-97F0-77B058EE5C49Q28210537-787555F9-2DCA-4763-BECF-A939A1FAD696Q28217761-5FD4E8EA-7C21-4EAF-BD3E-F2C3D34105E9Q28218201-06D3615D-67FA-4585-B686-C8F6F3FFD8B0Q28218952-CDAB9B54-1EB6-48FA-B530-484C7128E92FQ28219113-722D061F-C7C5-44E4-8CF8-BFE1A1A5BA08Q28220708-CBA0C366-F311-42F4-BD9C-4EF213B11A85Q28601060-9CF67C6C-0892-4FEE-96D2-D3F3822A2CDCQ28603125-D1A78B4B-AA86-4082-866F-365804805DE5Q30421742-0C468E80-4CBE-42ED-AAF7-0C86C8F97944Q30574994-CAD5191F-2ABB-46AF-9507-57A20461CB68Q30795407-E867974F-2F96-42AE-BF26-2ECF47CB6466Q31035351-AE985BB9-F771-4E5F-89AB-04003F0FE163Q31039802-F833E4E3-D701-4B24-B507-DBD8B1D8A3E7Q31171239-F64952DB-F2BE-4CD4-AD14-569DDAF68294Q33371866-E0EB6198-9EAF-4B12-88B6-E4AB5FB7B0FBQ33378276-83951CA5-016A-418C-A9E6-A6F26BAAD67AQ33383940-1E2CD575-6D5B-444D-B42F-F88ECD8B2174Q33394098-917FA50E-D8F8-45D2-9CBA-05A67C280101Q33569289-AC49A332-6851-431C-BB29-706EAA8D5140Q33621896-94996CE0-9594-40C9-8181-59E4439FBF7C
P50
name
Steven R Steinhubl
@ast
Steven R Steinhubl
@en
Steven R Steinhubl
@nl
type
label
Steven R Steinhubl
@ast
Steven R Steinhubl
@en
Steven R Steinhubl
@nl
prefLabel
Steven R Steinhubl
@ast
Steven R Steinhubl
@en
Steven R Steinhubl
@nl